Citation & Authors
Lancet Reg Health West Pac. 2024;42:100925.
ABSTRACT · RESEARCH SUMMARY
Research summary
385 Asian patients with RA who had an inadequate response or intolerance to methotrexate were randomized to peficitinib 100 mg, 150 mg, or placebo. At week 24 or early termination, ACR20 response rates were 56.6%, 56.3%, and 24.2%, respectively. Both doses were superior to placebo, but the higher dose showed no additional benefit. Herpes zoster-related disease occurred more frequently in the peficitinib groups and should be considered alongside efficacy.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
